Novartis AG ADR (NVS)vsSanara Medtech Inc (SMTI)
NVS
Novartis AG ADR
$148.38
-0.55%
HEALTHCARE · Cap: $273.77B
SMTI
Sanara Medtech Inc
$22.12
+5.48%
HEALTHCARE · Cap: $197.03M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 52540% more annual revenue ($56.58B vs $107.48M). NVS leads profitability with a 23.9% profit margin vs -31.2%. NVS trades at a lower P/E of 20.6x. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
SMTI
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Margin of Safety
+58.4%
Fair Value
$46.72
Current Price
$22.12
$24.60 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
18.6% revenue growth
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 2.9% — below average capital efficiency
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : SMTI
The strongest argument for SMTI centers on Revenue Growth. Revenue growth of 18.6% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : SMTI
The primary concerns for SMTI are EPS Growth, Market Cap, Return on Equity. A P/E of 358.3x leaves little room for execution misses. Debt-to-equity of 6.88 is elevated, increasing financial risk.
Key Dynamics to Monitor
NVS profiles as a declining stock while SMTI is a growth play — different risk/reward profiles.
SMTI carries more volatility with a beta of 1.19 — expect wider price swings.
SMTI is growing revenue faster at 18.6% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 29/100), backed by strong 23.9% margins. SMTI offers better value entry with a 58.4% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Sanara Medtech Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Sanara MedTech Inc. develops, markets and distributes skin and wound care products to physicians, hospitals, clinics, and post-acute care settings in the United States. The company is headquartered in Fort Worth, Texas.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?